Home Newsfeeds Evercore ISI Group Initiates Coverage On ProKidney with Outperform Rating

Evercore ISI Group Initiates Coverage On ProKidney with Outperform Rating

Evercore ISI Group analyst Jonathan Miller initiates coverage on ProKidney (NASDAQ:PROK) with a Outperform rating.

byBenzinga Newsdesk

September 2, 2022

1 minute read

Evercore ISI Group analyst Jonathan Miller initiates coverage on ProKidney (NASDAQ:PROK) with a Outperform rating.

Analyst Ratings

11 Analysts Have This to Say About Analog Devices

By Benzinga Insights

June 13, 12:01 PM

Analog Devices (NASDAQ:ADI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

ADI

FSD Pharma Provides Update On Proposed Dividend Distribution For Shareholders Of FSD Pharma To Receive Shares Of Celly Nutrition On A One For One Basis

By Benzinga Newsdesk

November 7, 12:47 PM

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions,is pleased to announce that the

CSE:HUGE

EXCLUSIVE: Ocean Biomedical’s Co-Founder Outlines Detailed Data From Malaria Vaccine At Conference

By Vandana Singh

April 25, 7:30 AM

Ocean Biomedical Inc's (NASDAQ: OCEA) co-founder, Jonathan Kurtis, presented details of the company's malaria vaccine and treatment approach at the PATH Malaria's annual retreat in Washington, DC.

OCEA

Morgan Stanley Maintains Equal-Weight on Park Hotels & Resorts, Raises Price Target to $15

By Benzinga Newsdesk

February 7, 10:33 AM

Morgan Stanley analyst Stephen Grambling maintains Park Hotels & Resorts (NYSE:PK) with a Equal-Weight and raises the price target from $14 to $15.

Evercore ISI Group Initiates Coverage On ProKidney with Outperform Rating

Related Posts

11 Analysts Have This to Say About Analog Devices

FSD Pharma Provides Update On Proposed Dividend Distribution For Shareholders Of FSD Pharma To Receive Shares Of Celly Nutrition On A One For One Basis

EXCLUSIVE: Ocean Biomedical’s Co-Founder Outlines Detailed Data From Malaria Vaccine At Conference

Morgan Stanley Maintains Equal-Weight on Park Hotels & Resorts, Raises Price Target to $15